Ownership history in XTX Topco Ltd Β· 10 quarters on record
This page tracks every 13F SEC filing in which XTX Topco Ltd reported a position in IMMUNIC INC (IMUX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π XTX Topco Ltd underperformed the S&P 500 by β71.7% annually on this IMUX position. Timing score: 44% (4/9 decisions correct). Average cost basis: $1.46. Maximum drawdown during holding period: β84.7%.
β Significantly underperformed the S&P 500 by 71.7% ann.
9 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
4 of 9 add/trim decisions correct
Best entry: $0.53 (2025 Q4) Β· Worst: $3.47 (2022 Q2)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
7 adds Β· 3 trims. Bought during 4 of 6 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size